Skip to main content
ScholarsBetaWeill Cornell Medicine

Publications

60 publications

Funding

1 grant
Completed grants (1)
  • Sub-PI
    Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT) - Project 1
    National Cancer Institute · 2012–2016 · via Fred Hutchinson Cancer Research Center· 3 renewals
    U54CA163438-05EWO

Clinical research

10 studies
Completed & closed trials (10)
  • PI
    Indications for Use of CD34 Selection Column (CliniMACS-Miltenyi Biotec)
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2026)
  • PI
    A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
    PHASE1 · Precision BioSciences, Inc. · IRB STUDY CLOSURE (as of 2025)
    Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    NCT03666000
  • PI
    A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer
    PHASE1 · AffyImmune Therapeutics Inc. · IRB STUDY CLOSURE (as of 2025)
    Anaplastic Thyroid Cancer; Relapsed/Refractory Poorly Differentiated Thyroid Cancer
    NCT04420754
  • PI
    A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
    PHASE2 · Marker Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2024)
    Acute Myeloid Leukemia; Stem Cell Transplantation
    NCT04511130
  • PI
    Phase I Study of Itacitinib in Combination With Tocilizumab for the Treatment of Steroid Refractory Acute Graft Versus Host Disease
    PHASE1 · Columbia University Medical Center · IRB STUDY CLOSURE (as of 2024)
    Steroid Refractory GVHD; Graft Vs Host Disease
    NCT04070781
  • PI
    A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T)
    PHASE3 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2023)
    Acute Myeloid Leukemia (AML); Cancer
    NCT04161885
  • PI
    Compassionate Use of Out-of-Specification Brexucabtagene autoleucel (KTE-X19) for Treatment of Mantle Cell Lymphoma in Patient T-K
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
  • PI
    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    PHASE3 · Millennium Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2021)
    Hematopoietic Stem Cells
    NCT03657160
  • PI
    A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
    PHASE1 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2021)
    Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Relapsed Adult Acute Myeloid; Myelodysplastic Syndromes, Previously Treated
    NCT03393611
  • PI
    A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
    PHASE3 · Kiadis Pharma · IRB STUDY CLOSURE (as of 2020)
    Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome
    NCT02999854